Non-cognitive benefits of galantamine (Reminyl®) treatment in vascular dementia

Acta Neurologica Scandinavica, Supplement

Volumn 106, Issue 178, 2002, Pages 19-24

  Kurz, Alexander ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acetylcholinesterase inhibitors; Galantamine; Non cognitive symptoms; Treatment; Vascular dementia

Indexed keywords

GALANTAMINE; PLACEBO; CHOLINESTERASE INHIBITOR; NOOTROPIC AGENT;

BEHAVIOR; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DETERIORATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MULTIINFARCT DEMENTIA; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; TREATMENT INDICATION; VOMITING; WELLBEING; AGED; ARTICLE; CLASSIFICATION; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT; SOCIAL BEHAVIOR; TREATMENT OUTCOME; ALZHEIMER DISEASE; BEHAVIOR CHANGE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; SYMPTOM;

ACTIVITIES OF DAILY LIVING; AGED; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DEMENTIA, VASCULAR; GALANTAMINE; HUMANS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; QUALITY OF LIFE; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

EID: 0036967157     PISSN: 00651427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. GAUTHIER S, FERRIS S. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. Int J Clin Pract Suppl 2001;120:29-39.
2. TOGASHI H, KIMURA S, MATSUMOTO M, YOSHIOKA M, MINAMI M, SAITO H. Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke 1996;27:520-5.
3. TOGASHI H, MATSUMOTO M, YOSHIOKA M, HIROKAMI M, MINAMI M, SAITO H. Neurochemical profiles in cerebrospinal fluid stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994;166:117-20.
4. KIMURA S, SAITO H, MINAMI M et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000;153:167-78.
5. MAELICKE A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl™). Int J Clin Pract Suppl 2001;120:24-8.
6. ERKINJUNTTI T. Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD. Int J Clin Pract Suppl 2001;120:14-23.
7. CHUI H, GONTHIER R. Natural history of vascular dementia. Alzheimer Dis Assoc Disord 1999;13(Suppl. 3):S124-30.
8. MENDEZ MF, YOUNESI FL, PERRYMAN KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999;11:268-70.
9. MORETTI R, TORRE P, ANTONELLO RM, CAZZATO G. Rivastigmine in subcortical vascular dementia. a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001;8:361-2.
10. KUMAR V, ANAND R, MESSINA J, HARTMAN R, VEACH J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000;7:159-69.
11. SAMOCHOCKI M, ZERLIN M, JOSTOCK R et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl 2000;176:68-73.
12. ERKINJUNTTI T, KURZ A, GAUTHIER S, BULLOCK R, LILIENFELD S, DAMARAJU CV. Galantamine is efficacious in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Lancet 2002;359:1283-90.
13. SCHNEIDER LS, OLIN JT, DOODY RS et al. Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(Suppl. 2):S22-32.
14. BARCLAY LL, ZEMCOV A, BLASS JP, SANSONE J. Survival in Alzheimer's disease and vascular dementia. Neurology 1985;35:834-40.
15. AHARON-PERETZ J, KILOT D, TOMER R. Behavorial differences between white matter lacunar dementia and Alzheimer's disease: a comparison on the neuropsychiatric inventory. Dement Geriatr Cogn Disord 2000;11:294-8.
16. CUMMINGS JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48:S10-S16.
17. KUNIK ME, HUFFMAN JC, BHARANI N et al. Behavorial disturbances in geropsychiatric inpatients across dementia types. J Geriatr Psychiatry Neurol 2000;13:49-52.
18. LYKETSOS CG, STEINBERG M, TSCHANZ JT et al. Mental and behavorial disturbances in dementia: findings from the Cache county study on memory and aging. Am J Psychiatry 2000;157:708-14.
19. LEHFELD H, REISBERG B, FINKEL S et al. Informant-rated activities-of-daily-living (ADL) assessments: results of a study of 141 items in the USA, Germany, Russia, and Greece for the International ADL Scale Development Project. Alzheimer Dis Assoc Disord 1997;11:S39-44.
20. GELINAS I, GAUTHIER L, MCINTYRE M, GAUTHIER S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999;53:471-81.
21. TARIOT PN, SOLOMON PR, MORRIS JC, KERSHAW P, LILIENFELD S, DING C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76.
22. RASKIND MA, PESKIND ER, WESSEL T, YUAN W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261-8.
23. WILCOCK GK, LILIENFELD S, GAENS E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000;321:1445-9.
24. TORFS K, FELDMAN H. 12-Month decline in cognitive and daily function in patients with mild-to-moderate Alzheimer's disease: two randomized placebo-controlled studies. Poster presented at the World Alzheimer Congress, Washington, DC; 2000.
25. SCHULZ R, BEACH SR. Caregiving as a risk factor for mortality. JAMA 1999;23:2215-9.
26. BULLOCK R, LILIENFELD S. Galantamine shows promising results in probable vascular dementia and Alzheimer's disease with cerebrovascular components. Poster presented at. XVII. World Congress of Neurology, London, UK; 2001.